

# AstraZeneca Development Pipeline

## 28 January 2010

### Line Extensions

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
<b>Cardiovascular</b>					
<i>Crestor</i>	statin	outcomes in subjects with elevated CRP	III	Filed	Filed
Onglyza/ metformin FDC <sup>#</sup>	DPP-4 inhibitor + biguanide FDC	diabetes	III	3Q 2010	Filed
Dapagliflozin/ metformin FDC <sup>#</sup>	SGLT2 inhibitor + biguanide FDC	diabetes	III	2H 2011	2H 2011
<b>Gastrointestinal</b>					
<i>Nexium</i>	proton pump inhibitor	peptic ulcer bleeding	III	Launched	Filed
<i>Axanum</i>	proton pump inhibitor + low dose aspirin FDC	low dose aspirin associated peptic ulcer	III	3Q 2010*	Filed
<b>Neuroscience</b>					
<i>Seroquel</i>	D <sub>2</sub> /5HT <sub>2</sub> antagonist	bipolar maintenance	III	Launched	Launched
<i>Seroquel XR</i>	D <sub>2</sub> /5HT <sub>2</sub> antagonist	major depressive disorder	III	Filed	Approved
<i>Seroquel XR</i>	D <sub>2</sub> /5HT <sub>2</sub> antagonist	generalised anxiety disorder	III	Filed	Filed
<b>Oncology &amp; Infection</b>					
<i>FluMist</i>	live, attenuated, intranasal influenza virus vaccine	influenza	III	Filed	Launched
<i>Iressa</i>	EGFR tyrosine kinase inhibitor	NSCLC	III	Launched	TBD
<i>Faslodex</i>	oestrogen receptor antagonist	first line advanced breast cancer	III		
<i>Faslodex</i>	oestrogen receptor antagonist	high dose (500mg) second line advanced breast cancer	III	Filed	Filed
Motavizumab <sup>#</sup>	humanized MAb binding to RSV F protein	early and late treatment of RSV in paeds >1 yr	II		2015
MEDI-3414	H1N1 influenza	pandemic flu prevention	III		Launched

<sup>#</sup>Partnered product

\*Previously submission was indication only. Now covers fixed dose combination

## NCEs

### Phase III/Registration

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
<b>Cardiovascular</b>					
Onglyza <sup>#</sup>	DPP-4 inhibitor	diabetes	III	Launched	Launched
<i>Brilinta/Brilique</i>	ADP receptor antagonist	arterial thrombosis	III	Filed	Filed
<i>Certriad</i> <sup>#</sup>	statin + fibrate fixed combination	dyslipidaemia	III		Filed
Dapagliflozin <sup>#</sup>	SGLT2 inhibitor	diabetes	III	4Q 2010	4Q 2010*
<b>Neuroscience</b>					
<i>Vimovo</i> <sup>#</sup>	naproxen + esomeprazole	signs and symptoms of OA, RA and AS	III	Filed	Filed
<b>Oncology &amp; Infection</b>					
Motavizumab <sup>#</sup>	humanized MAb binding to RSV F protein	RSV prevention	III	4Q 2010	Filed
<i>Zactima</i>	VEGFR/EGFR tyrosine kinase inhibitor with RET kinase activity	medullary thyroid cancer - orphan	III	3Q 2010	3Q 2010
<i>Recentin</i>	VEGFR tyrosine kinase inhibitor	CRC	III	4Q 2010	4Q 2010
<i>Recentin</i>	VEGFR tyrosine kinase inhibitor	recurrent glioblastoma - orphan	III	4Q 2010	4Q 2010
Zibotentan (ZD4054)	endothelin A receptor antagonist	castrate resistant prostate cancer	III	1H 2011	1H 2011
Ceftaroline <sup>#</sup>	affinity to penicillin-binding proteins	pneumonia /skin infections	III	3Q 2010	NA

<sup>#</sup>Partnered product

\*Timing subject to CV event rate

## NCEs

### Phases I and II

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
<b>Cardiovascular</b>					
AZD0837	direct thrombin inhibitor	thrombosis	II		
AZD6370	GK activator	diabetes	II		
AZD1656	GK activator	diabetes	II	2015	2015
AZD6482	PI3K-beta inhibitor	thrombosis	I		
AZD4017	11BHSD inhibitor	diabetes/obesity	I		
AZD6714	GK activator	diabetes	I		
AZD8329	11BHSD inhibitor	diabetes/obesity	I		
AZD7687	diacylglycerol acyl transferase -1 inhibitor	diabetes/obesity	I		
<b>Gastrointestinal</b>					
Lesogaberan (AZD3355)	GABA <sub>B</sub> agonist	GERD	II	2013	2013
AZD1386	vanilloid receptor antagonist	GERD	II		
AZD2066	metabotropic glutamate receptor 5 antagonist	GERD	I		
AZD2516	metabotropic glutamate receptor 5 antagonist	GERD	I		

## NCEs

### Phases I and II (continued)

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
<b>Neuroscience</b>					
AZD3480 <sup>#</sup>	Alpha4/beta2 neuronal nicotinic receptor agonist	ADHD	II		
AZD6765	NMDA receptor antagonist	major depressive disorder	II	2013	2013
AZD2327	enkephalinergic receptor modulator	anxiety and depression	II		
AZD2066	metabotropic glutamate receptor 5 antagonist	chronic neuropathic pain	II		
AZD8529	glutamatergic modulator	schizophrenia	II		
NKTR-118 <sup>#</sup>	oral peripherally-acting opioid antagonist	opioid-induced constipation	II	2013	2013
TC-5214 <sup>#</sup>	nicotinic ion channel blocker	major depressive disorder	II	2014	2012
TC-5619 <sup>#</sup>	Alpha7 neuronal nicotinic receptor agonist	cognitive disorders in schizophrenia	II		
AZD7268	enkephalinergic receptor modulator	depression/anxiety	II		
AZD1446 <sup>#</sup>	Alpha4/beta2 neuronal nicotinic receptor agonist	Alzheimer's disease/ADHD	II		
AZD3241	myeloperoxidase (MPO) inhibitor	Parkinson's disease	I		
AZD6280	GABA receptor subtype partial agonist	anxiety	I		
AZD2516	metabotropic glutamate receptor 5 antagonist	chronic neuropathic pain	I		
AZD3043 <sup>#</sup>	GABA-A receptor modulator	short acting sedative and anaesthetic	I		
AZD8418	glutamatergic modulator	schizophrenia	I		
AZD2423	chemokine antagonist	chronic neuropathic pain	I		

<sup>#</sup>Partnered product

NCEs

***Phases I and II (continued)***

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
<b>Oncology &amp; Infection</b>					
<i>Recentin</i>	VEGFR tyrosine kinase inhibitor	NSCLC	II	2013	2013
<i>CytoFab</i> <sup>#</sup>	anti-TNF-alpha polyclonal antibody	severe sepsis	II	2014	2014
AZD6244 <sup>#</sup> (ARRY-142886)	MEK inhibitor	solid tumours	II	2014	2014
Olaparib	PARP inhibitor	gBRCA breast cancer	II	2012	2012
Olaparib	PARP inhibitor	serous ovarian cancer	II	2014	2014
AZD7295	NS 5A inhibitor	hepatitis C	II	2015	2015
AZD1152	aurora kinase inhibitor	haematological malignancies	II	2012	2012
MEDI-3250	flu vaccine (quadravalent)	seasonal influenza	II		
CAZ104 <sup>*#</sup>	beta lactamase inhibitor/cephalosporin	serious infections	II	2012	NA
AZD4769	EGFR tyrosine kinase inhibitor	solid tumours	I		
AZD8931	erbB kinase inhibitor	solid tumours	I		
AZD7762	CHK1 kinase inhibitor	solid tumours	I		
AZD8330 <sup>#</sup> (ARRY-424704)	MEK inhibitor	solid tumours	I		
CAT-8015	recombinant immunotoxin	haematological malignancies	I		
MEDI-534	RSV/PIV-3 vaccine	RSV/PIV prophylaxis	I		
MEDI-560	PIV-3 vaccine	intranasal immunisation	I		
MEDI-550	pandemic influenza virus vaccine	pandemic influenza vaccine	I		
MEDI-557	YTE – extended half-life RSV MAb	RSV prophylaxis	I		
AZD8055	TOR kinase inhibitor	range of tumours	I		
MEDI-559	RSV vaccine	RSV prophylaxis	I		
MEDI-573	IGF	solid tumours	I		
MEDI-575	PDGFR-alpha	solid tumours	I		
AZD1480	JAK2 inhibitor	myeloproliferative diseases /solid tumours	I		
AZD5847	Oxazolidinone antibacterial inhibitor	tuberculosis	I		
AZD4547	FGFR tyrosine kinase inhibitor	solid tumours	I		
MEDI-547 <sup>#</sup>	EphA2 conjugate	solid tumours	I		
AZD9742	BTGT4 IV	MRSA	I		
CEF104 <sup>*#</sup>	beta lactamase inhibitor/cephalosporin	MRSA	I		NA
AZD2014	MTOR inhibitor	solid tumours	I		

AZD6244 (ARRY- 142886) /MK2206#	MEK/AKT inhibitor	solid tumours	I		
--	-------------------	---------------	---	--	--

\*Subject to review under the Hart Scott Rodino Act

#Partnered product

NCEs

***Phases I and II (continued)***

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
<b>Respiratory &amp; Inflammation</b>					
AZD1981	CRTh2 receptor antagonist	asthma/COPD	II		
MEDI-528 <sup>#</sup>	anti-IL-9 antibody	asthma	II		
CAT-354	anti-IL-13 antibody	asthma	II		
AZD9668	neutrophil elastase inhibitor	COPD	II	2014	2014
AZD1236	matrix metallo-proteinase inhibitor	COPD	II		
AZD3199	iLABA	asthma/COPD	II		
MEDI-563 <sup>#</sup>	anti-IL-5R antibody	asthma	II		
MEDI-545 <sup>#</sup>	anti-IFN-alpha antibody	SLE, myositis	II		
AZD9164	LAMA	COPD	II		
AZD8848	Toll like receptor 7 agonist	asthma	II		
CAM-3001 <sup>#</sup>	anti-GM-CSFR	rheumatoid arthritis	I		
AZD8566	CCR5	COPD	I		
AZD8075	CRTh2 antagonist	asthma/COPD	I		
AZD5985	CRTh2 antagonist	asthma/COPD	I		
AZD2551	protease inhibitor	COPD	I		
AZD5423	iSEGRA	COPD	I		
AZD5122	CXCR2	COPD	I		
AZD8683	Muscarinic antagonist	COPD	I		
AZD5069	CXCR2	COPD	I		
MEDI-546 <sup>#</sup>	anti-IFNaR MAb	scleroderma	I		

<sup>#</sup>Partnered product

## AstraZeneca Development Pipeline

### Discontinued Projects vs 30 July 2009 HY

#### Cardiovascular/Gastrointestinal

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD1305	arrhythmias

#### Neuroscience

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD5904	multiple sclerosis
NCE	AZD6088	chronic neuropathic pain
NCE	AZD1386	chronic neuropathic pain
NCE	AZD7325	anxiety
NCE	AZD4694	Alzheimer's disease PET diagnostic

#### Oncology & Infection

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD9639	RSV treatment
NCE	CMV Vaccine	cytomegalovirus
NCE	saracatinib	solid tumours
NCE	<i>Zactima</i>	NSCLC

#### Respiratory & Inflammation

NCE/Line Extension	Compound	Area Under Investigation
LCM	<i>Symbicort</i> pMDI EU	asthma
LCM	<i>Symbicort</i> pMDI EU	COPD

#### Comments

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Compounds in development are displayed by phase.

Key:

MAA – Marketing Authorisation Application (Europe).

NDA – New Drug Application/Biologics Licensing Application (USA).